AlphAIAlphAI — Financial news for AI agents
biz.chosun.comNOV 32 min read$TEVA

Samsung Bioepis teams with Teva to sell two US biosimilars

Samsung Bioepis (0126Z0) and Teva Pharmaceuticals agreed to commercialize two biosimilars in the U.S. Samsung Bioepis will handle development and supply, while Teva manages sales. The deal is valued at up to $420 million, including upfront and milestone payments. The biosimilars, Renflexis and Eticovo, treat autoimmune diseases and have FDA approval.

Original reporting
biz.chosun.com
Published Nov 3, 2026, 8:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Samsung Bioepis teams with Teva to sell two US biosimilars — source image
Source · biz.chosun.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The partnership provides Teva with new product launches and a sizable upfront payment, likely supporting its earnings outlook.

02

Market read

The deal adds $420 million of potential revenue for Teva and expands Samsung Bioepis' U.S. market presence, relevant for biotech and pharma investors.

03

What to watch

Potential cannibalization of existing Teva biosimilar sales and integration costs.

Relevance 7/10Novelty 8/10Timing: immediate, as the upfront payment is due within 30 days

Background

Samsung Bioepis, a joint venture of Samsung and Biogen, expands its U.S. footprint by partnering with Teva for two autoimmune disease biosimilars.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva will handle U.S. sales for two Samsung Bioepis biosimilars, a partnership worth up to $420 million.

Expected impact

likely upside as the market prices in the partnership revenue potential

Evidence & confidence

Up‑front payment of $75 million and $270 million in sales milestones provide material upside for Teva's upcoming quarters.

Market effects

Sector

Strengthens the U.S. biosimilar sector and may pressure competitors on pricing.

Regional

Boosts South Korean biotech exposure through Samsung Bioepis partnership.

Global

Adds to global consolidation trend in biologics and biosimilars.

Counterpoint

What could challenge this read

If regulatory or reimbursement hurdles arise, the upside could be limited.

Key entities

  • company
    Samsung Bioepis

    South Korean biosimilar developer partnering with Teva.

  • company
    Teva Pharmaceuticals

    Global generic drugmaker handling U.S. sales of the biosimilars.

Read at source← All news

StorySamsung Bioepis and Teva sign up to $420 million U.S. biosimilar commercialization deal

Also covered by

1 outlet

Related articles

NOV 3
$TEVAMed

Teva Pharmaceutical Industries Ltd: Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva Pharmaceutical and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S. Teva will obtain rights to ETICOVO upon close and infliximab-abda in Q3 2027. The deal expands Teva's biosimilars portfolio as part of its Pivot to Growth strategy. Samsung Bioepis will retain regulatory and manufacturing responsibilities. Financial terms include an upfront payment and potential milestone payments.

finanznachrichten.de2 min
NOV 3
$TEVAMed

Teva to halt Phase II MSA therapy trial after futility analysis

Teva Pharmaceuticals halted a Phase II trial for emrusolmin (TEV-‘286) to treat multiple system atrophy (MSA) after an interim analysis suggested it would not meet its primary efficacy endpoint. The decision followed a recommendation from the independent data monitoring committee (IDMC), which found a low probability of demonstrating efficacy. No safety concerns were raised. Teva is developing the therapy in collaboration with privately managed biotechnology company MODAG.

clinicaltrialsarena.com4 min
NOV 2
$TEVAMed

Why is Teva Pharma ADR stock sliding today?

Teva Pharma ADR (TEVA) shares fell 0.8% to $41.76 after discontinuing a Phase 2 study for emrusolmin, an experimental drug. The decision followed an interim futility review. H.C. Wainwright initiated coverage with a Buy rating and $52 price target, citing growth in existing brands. The broader market advanced, with Teva's underperformance attributed to company-specific news.

investing.com6 min